Rachel Klemovitch, Assistant Editor03.07.24
Silk Road Medical has launched its Tapered ENROUTE Transcarotid Stent System for hospitals in the United States. This expands upon the company’s prior ENROUTE System, offering additional configurations to tailor to Transcarotid Artery Revascularization (TCAR) procedure to patient anatomy.
TCAR is a minimally invasive procedure designed to offer best-in-class stroke protection and minimize adverse events.
CEO Chas McKhann told the press, “As pioneers in stroke prevention, our product development efforts are focused on extending our lead in the minimally invasive treatment of carotid artery disease. New tapered configurations for our ENROUTE Transcarotid Stent System build upon the robust portfolio of Silk Road’s carotid solutions. We are pleased to bring this portfolio expansion to market as part of our commitment to offering a diverse toolkit for physicians, allowing them to address individual patient anatomy.”
ENROUTE Transcarotid Stent System is the only transcarotid stent system commercially available for patients at high risk and standard risk for adverse events from carotid endarterectomy (CEA).
This stent system features an optimized cell design balancing lesion coverage and anatomical conformability for long-term plaque stabilization. ENROUTE was built for TCAR with a short delivery system for precise and ergonomic stent delivery.
“The new tapered stent is a welcome addition to my TCAR toolkit, further differentiating the Company’s core product offering,” said Professor and Chief of Vascular Surgery, Cooper University Health Care, Joseph V. Lombardi. “The ENROUTE stent has always provided comprehensive lesion coverage and durable procedural outcomes, but I now have more options to customize treatment to each patient's anatomy.”
TCAR is a minimally invasive procedure designed to offer best-in-class stroke protection and minimize adverse events.
CEO Chas McKhann told the press, “As pioneers in stroke prevention, our product development efforts are focused on extending our lead in the minimally invasive treatment of carotid artery disease. New tapered configurations for our ENROUTE Transcarotid Stent System build upon the robust portfolio of Silk Road’s carotid solutions. We are pleased to bring this portfolio expansion to market as part of our commitment to offering a diverse toolkit for physicians, allowing them to address individual patient anatomy.”
ENROUTE Transcarotid Stent System is the only transcarotid stent system commercially available for patients at high risk and standard risk for adverse events from carotid endarterectomy (CEA).
This stent system features an optimized cell design balancing lesion coverage and anatomical conformability for long-term plaque stabilization. ENROUTE was built for TCAR with a short delivery system for precise and ergonomic stent delivery.
“The new tapered stent is a welcome addition to my TCAR toolkit, further differentiating the Company’s core product offering,” said Professor and Chief of Vascular Surgery, Cooper University Health Care, Joseph V. Lombardi. “The ENROUTE stent has always provided comprehensive lesion coverage and durable procedural outcomes, but I now have more options to customize treatment to each patient's anatomy.”